300272 Canature Health Technology
- 7.21
- +0.15+2.12%
Canature Health Technology News
Canature Health Technology (300272.SZ): Overseas income generally accounts for about 65% of total annual revenue.
Gelonghui November 15th | canature health technology (300272.SZ) stated during an investor survey on November 15, 2024, that overseas income generally accounts for about 65% of the total annual income. Currently, the company has already reached brand production agreements or sales framework agreements with many long-term important customers overseas, and is expected to continue to play a synergistic role, supporting the continuous improvement of market share in overseas markets.
canature health technology (300272): Overseas revenue contributes to the basic level of performance, which is affected by the losses of its subsidiaries.
The company's income performance fell short of expectations. canature health technology achieved revenue of 1.254 billion yuan in Q1-3 2024, a year-on-year increase of 1%; achieved net income attributable to the mother of 0.084 billion yuan, a year-on-year decrease of 35%; achieved non-net profit attributable to the mother of 0.81 billion yuan.
Canature Health Technology (300272): Operations stable, non-operational drag on performance.
Event overview The company released the third quarter report of 2024: 24Q1-Q3: total operating income of 1.254 billion yuan (YOY +1.00%), net income attributable to the parent company of 0.084 billion yuan (YOY-34.92%), after deducting non-recurring items.
Kaineng Health: Report for the third quarter of 2024
Canature Health Technology (300272.SZ) released performance for the first three quarters, with a net income of 84.165 million yuan, a decrease of 34.92%.
canature health technology (300272.SZ) released the third quarter report of 2024, the company's revenue for the first three quarters was 1...
Express News | Midday Announcement
Express News | Announcement Summary at Noon on September 4th: Canature Health Technology changes the source of convertible bonds to prioritize the use of repurchased shares.
Express News | Kaineng Convertible Bonds: Conversion rights will resume starting from September 4th.
Canature Health Technology (300272): Revenue performance exceeds expectations, providing high dividends to shareholders.
Investment Highlights: The company's revenue performance exceeded our expectations. Canature Health Technology achieved revenue of 0.829 billion yuan in H1 2024, a year-on-year increase of 4%; achieved net income attributable to the parent company of 57.03 million yuan, a year-on-year increase of 6%; achieved non-GAAP net income attributable to the parent company of 5 million yuan.
Canature Health Technology (300272): Stable operation and high dividend return to shareholders.
Event Overview: The company released its 2024 interim report: 24H1: revenue of 829 million yuan (YOY +4.23%), net income attributable to shareholders of 57 million yuan (YOY +6.04%), and non-GAAP net income attributable to shareholders of 540 million yuan.
Kaineng Health: 2024 Semi-Annual Report Summary
Kaineng Health: Semi-Annual Report 2024
Canature Health Technology (300272.SZ): The profit in the first half of the year was 57.0318 million yuan, a year-on-year increase of 6.04%.
On August 27, Canature Health Technology (300272.SZ) released its 2024 interim report, with the company's revenue for the reporting period at 829 million yuan, a year-on-year increase of 4.23%; the net income attributable to shareholders of the listed company was 57.0318 million yuan, a year-on-year increase of 6.04%; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 54.1168 million yuan, a year-on-year increase of 6.05%; and the basic earnings per share was 0.10 yuan/share. It plans to distribute a cash dividend of 0.5 yuan (including tax) per 10 shares to all shareholders.
Canature Health Technology (300272.SZ) released its performance for the first half of the year, with a net income of 57.0318 million yuan, a year-on-year increase of 6.04%.
Canature Health Technology (300272.SZ) released its 2024 semi-annual report, with revenue of 0.829 billion yuan, ...
Canature Health Technology (300272.SZ) offers whole-house water purification systems, whole-house water softeners, and pre-filters that do not involve wastage of water resources.
On August 6, GeLongHui reported that Canature Health Technology (300272.SZ) expressed on the investor interaction platform that the company has a wide range of products, covering eight major categories, 83 series, and more than 1700 varieties and specifications. Among them, whole-house water purification machines, whole-house softening machines, and pre-filter products do not involve waste water resources. The waste water ratio of RO reverse osmosis machines has always been at the forefront in the industry. On December 1, 2021, the National Market Supervision Administration and the National Standardization Management Committee released the "Water Efficiency Limit Values and Water Efficiency Grades of Water Purifiers", which will be implemented from July 1, 2022. This is a mandatory national standard.
Canature Health Technology (300272.SZ): completed repurchase, spent a total of 29.0567 million yuan to repurchase 7.0574 million shares.
Canature Health Technology (300272.SZ) announced that the actual share buyback period was from February 6, 2024 to February 20, 2024. The company repurchased a total of 7.0574 million shares, accounting for 1.2227% of the company's current total share capital, through the stock repurchase special securities account and centralized bidding trading method under the share buyback plan. The highest fill price was 4.446 yuan/share and the lowest fill price was 3.84 yuan/share, with a total amount paid of 29.0567 million yuan (excluding transaction costs). The share repurchase plan will take effect on August 2, 2024.
Canature health technology (300272.SZ): For many years, the company's export revenue has accounted for more than 60%.
Canature Health Technology (300272.SZ) stated on its investor platform that for many years, the company's export revenue accounted for more than 60%. Settlement currencies are in US dollars and euros, and mainly deposited domestically. Considering recent exchange rates and differences in deposit and loan interest rates, the company chose to hold foreign currencies, as well as borrowing in renminbi for daily operations, and timely foreign exchange settlement based on market conditions and liquidity. Domestic and foreign currency deposits are demand deposits, with unrestricted liquidity and no outstanding approvals pending.
Canature Health Technology (300272.SZ): Overseas orders are full, Europe and Asia orders are completed locally in Shanghai or Jiangsu.
On July 16, 2024, Canature Health Technology (300272.SZ) conducted an investor survey regarding "Overseas situation and production line situation?". The company replied that overseas orders are full, and European and Asian orders are completed locally in Shanghai or Jiangsu with a stable delivery period. Canature North America has an assembly line for core components from domestic warehouses to the assembly line.
Canature Health Technology (300272.SZ): The RO reverse osmosis water purifier uses RO reverse osmosis technology.
On July 17th, Gelonhui reported that an investor had asked Canature Health Technology (300272.SZ) on the investor interaction platform, "Can the company's products filter bromate?" The company replied that RO reverse osmosis is an efficient membrane separation technology that can remove various ions and organic matter in water, including bromate, to achieve safe levels. The company's RO reverse osmosis water purifier uses RO reverse osmosis technology.
Canature Health Technology (300272.SZ) has repurchased 1.2227% of its shares.
Canature Health Technology (300272.SZ) announced on July 2nd that the company repurchased 7.0574 million shares of its own stock through a repurchase dedicated securities account using centralized bidding trading method, which accounted for 1.2227% of the company's total equity. The highest fill price was 4.446 yuan/share, and the lowest fill price was 3.84 yuan/share. The total amount paid was 29,056,700 yuan (excluding transaction fees).
No Data
